Literature DB >> 10708463

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

J J Kim1, J S Yang, T C VanCott, D J Lee, K H Manson, M S Wyand, J D Boyer, K E Ugen, D B Weiner.   

Abstract

An important limitation of DNA immunization in nonhuman primates is the difficulty in generating high levels of antigen-specific antibody responses; strategies to enhance the level of immune responses to DNA immunization may be important in the further development of this vaccine strategy for humans. We approached this issue by testing the ability of molecular adjuvants to enhance the levels of immune responses generated by multicomponent DNA vaccines in rhesus macaques. Rhesus macaques were coimmunized intramuscularly with expression plasmids bearing genes encoding Th1 (interleukin 2 [IL-2] and gamma interferon)- or Th2 (IL-4)-type cytokines and DNA vaccine constructs encoding human immunodeficiency virus Env and Rev and simian immunodeficiency virus Gag and Pol proteins. We observed that the cytokine gene adjuvants (especially IL-2 and IL-4) significantly enhanced antigen-specific humoral immune responses in the rhesus macaque model. These results support the assumption that antigen-specific responses can be engineered to a higher and presumably more desirable level in rhesus macaques by genetic adjuvants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708463      PMCID: PMC111847          DOI: 10.1128/jvi.74.7.3427-3429.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Direct gene transfer into nonhuman primate myofibers in vivo.

Authors:  S Jiao; P Williams; R K Berg; B A Hodgeman; L Liu; G Repetto; J A Wolff
Journal:  Hum Gene Ther       Date:  1992-02       Impact factor: 5.695

2.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

3.  Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

Authors:  Y H Chow; W L Huang; W K Chi; Y D Chu; M H Tao
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Protection against vaginal SIV transmission with microencapsulated vaccine.

Authors:  P A Marx; R W Compans; A Gettie; J K Staas; R M Gilley; M J Mulligan; G V Yamshchikov; D Chen; J H Eldridge
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

7.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.

Authors:  J I Sin; J J Kim; J D Boyer; R B Ciccarelli; T J Higgins; D B Weiner
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

10.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

View more
  11 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

Review 3.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

4.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Authors:  Yao Ma; Huai-Jie An; Xiao-Qi Wei; Qing Xu; Yun-Zhou Yu; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.

Authors:  John P Bilello; Julieta M Manrique; Young C Shin; William Lauer; Wenjun Li; Jeffrey D Lifson; Keith G Mansfield; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-09-07       Impact factor: 5.103

Review 7.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.

Authors:  D Marsac; D Loirat; C Petit; O Schwartz; M-L Michel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs.

Authors:  Sumit Choudary; P Ravikumar; C Ashok Kumar; V V S Suryanarayana; G R Reddy
Journal:  Virus Genes       Date:  2008-05-31       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.